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Aims Brugada syndrome (BrS) is a life-threatening arrhythmia disorder associated with autosomal-dominant mutations in
the SCN5A gene. We aimed to characterize the diagnostic challenges and clinical manifestations of a novel SCN5A
mutation associated with BrS.
Methods
and results
From a novel SCN5A mutation (c.664C.T; p.Arg222X) identified in a proband with the characteristic electrocardio-
graphic pattern and the history of sudden collapse, 122 family members were studied including 40 carriers of the
mutation. The electrocardiographic diagnosis of BrS requires type 1 Brugada electrocardiogram (ECG) pattern in
.1 right precordial lead (V1–V3), but recently an isolated lead with coved-type ECG was proposed to be
enough for the diagnosis. In this family, these proposed criteria (PC) were more sensitive in detecting mutation car-
riers than the conventional criteria without repercussion on the specificity. Carriers had, on average, longer P-wave
duration, PR, and QRS intervals and higher transmural dispersion of repolarization. The prevalence of late potentials
was higher in carriers, and individual signal average ECG (SAECG) parameters (QRSf, LAS, and RMS40) also were
related to SCN5A gene mutation. Three non-carriers were found to be affected by BrS, two with a spontaneous
type 1 ECG with alternative placement of the precordial electrodes, and one only after the pharmacological provoca-
tive test, suggesting that other genes may play a role in the pathophysiology of this disease.
Conclusion The PC for BrS diagnosis should be implemented. Some parameters from the spontaneous ECG and the SAECG are
more effective tools than the characteristic repolarization pattern to discriminate between carriers of SCN5A
mutations.
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Introduction
Brugada syndrome (BrS) is characterized by a distinctive coved-
type ST-segment elevation in the right precordial leads and a
high risk of ventricular arrhythmias and sudden cardiac death
(SCD) in individuals with a structurally normal heart.1– 4 The
worldwide prevalence is difficult to determine because the
electrocardiogram (ECG) pattern may be dynamic or concealed,
but it is estimated at 1–5 per 10 000 habitants, with male domin-
ance (8 : 1 ratio), uneven geographical distribution, and with lower
prevalence in the West and higher in Asia.5 The BrS is a hereditary
condition (although acquired forms have been reported) with
autosomal-dominant inheritance and incomplete penetrance (it is
estimated that up to 25% of individuals genetically affected do
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not have BrS). Mutations in the SCN5A, the gene that encodes the
alpha subunit of the cardiac sodium channel gene, have been found
in 18–30% of patients.6– 8
Arrhythmic events tend to manifest around third and fourth
decades of life and BrS is thought to be responsible for 4–12%
of all cases of SCD and up to 20% in those with structurally
normal hearts. Assessing the disease-associated arrhythmic risk, es-
pecially in asymptomatic patients, is a controversial debate and cur-
rently is based on the spontaneous ECG, the history of syncope or
aborted SCD, and the inducibility of ventricular arrhythmias during
electrophysiological study.9 This paper presents a large Portuguese
family with a novel SCN5A mutation related to BrS and evaluates
different diagnostic criteria regarding this entity and the ability to
predict SCN5A mutation carriers.
Materials and methods
All investigations conformed to principles defined in the Helsinki Dec-
laration. One hundred and twenty-two members of a three-generation
Portuguese family were investigated, and informed written consent
was obtained from each member. Genetic counselling was offered to
every family member. The clinical assessment included a complete
medical history, physical examination, 12-lead ECG recordings
obtained at different times, and echocardiographic scanning. Electro-
cardiogram recordings were performed in the absence of antiarrhyth-
mic drugs and at normal electrolyte levels. All ECGs were recorded in
a supine position at normal body temperatures (,37.58C). Recording
speed was 25 mm/s, and all ECGs were analysed by two experienced
physicians. Only coved-type ECG pattern with .2 mm ST-segment
elevation with an upward convexity to an inverted T-wave in at least
two right precordial leads was defined as diagnostic (type 1 ECG).
Types 2 and 3 patterns have a saddle back ST-T-wave configuration
in which the elevated ST-segment descends towards the baseline
and then rises again to an upright or biphasic T-wave. The ST-segment
is elevated ≥1 mm in type 2 and ,1 mm in type 3, and these two pat-
terns only were considered suggestive. Heart rate, width of P-wave, PR
interval, QRS duration, and QT interval corrected for heart rate using
Bazett’s formula (QTc) were measured in limb lead II. QTc intervals
were averaged from five consecutive beats. Signal average ECG
(SAECG) was obtained with time-domain analysis, and three measures
were made: filtered QRS (fQRS) duration, low-amplitude signal (LAS)
duration, and root-mean-square (RMS) of the voltage in the last 40 ms
of the fQRS (RMS 40). The graphic representation of late potentials as
well as the numerical values of signal-averaged ECG parameters was
manually checked. Late potentials were defined when at least two of
the three criteria were found: fQRS .114 ms, RMS40 ,20, and
LAS .38 ms.
Genetic testing
Genomic DNA was extracted from 5 mL of peripheral blood using an
automated procedure (Roche magnapure). Mutation screening was
performed on the complete SCN5A coding sequence of the index
case, and primers were designed to individually amplify each SCN5A
exon, including exon/intron boundaries. The remaining members of
the family were analysed only for exon 6. Amplification products
were purified and sequenced using the ABI Prism Dye Terminator
Cycle Sequencing kit (Perkin-Elmer, Foster City, CA, USA) and an
Applied Biosystems 3130xl Genetic Analyzer. Sequencing was per-
formed on both strands using the original primers, and every case
was polymerase chain reaction/sequenced twice independently.
Statistical analysis
Results for continuous measurements are given as mean+ standard
deviation. Differences between means were accessed through the
Mann–Whitney test, and comparisons of different sensitivities and
specificities were performed using McNemar test and binominal test
taking as reference value one of the sensitivity/specificity. A value of
P , 0.05 was considered statistically significant. The SPSSw version
17 software package was used.
Results
Mutation screening
The proband (III25, Figure 1) was a 35-year-old man, taking no
medication on a regular basis, with a routine ECG with type 1
Brugada pattern in leads V1 and V2, the characteristic phenotype
of BrS. Seven months earlier, he had had an episode of syncope.
The diagnosis also was supported by the patient’s family history
of five known cases of SCD under the age of 45 years, four
during their sleep among relatives on the maternal side of the
family: a male cousin, two uncles, and two great uncles. His mater-
nal grandmother had five siblings (all deceased, including the above
two great uncles), and his mother had 10 siblings and 21 cousins,
making a total of 124 possibly affected individuals.
Genetic analysis led to the discovery of a nonsense mutation in
exon 6 of the SCN5A gene, leading to the formation of a prema-
ture stop codon at position 222 of the protein (c.664C.T;
p.Arg222X).
Genetic testing revealed 42 family members carrying this specific
mutation of the SCN5A gene: 24 women and 18 men. Two women
carrying the mutation refused to perform further analysis. There-
fore, 122 individuals (Figure 1) were enrolled in additional
studies, including 40 carriers of the SCN5A mutation (22 women,
34 + 18.1 years, and 18 men, 27.9 + 17.1 years) and 82 non-
carriers (40 women, 31+ 16.1 years, and 42 men, 28.6+15.4
years).
Electrocardiogram screening
A spontaneous ECG was recorded in 122 family members with the
right precordial leads (V1 and V2) carefully placed in the fourth
intercostal space (IS) parasternally (using anatomic references).
Table 1 presents the number of mutation carriers detected with
the conventional criteria (CC) (type 1 ECG .1 right precordial
lead) against the proposed criteria10 (PC) (type 1 ECG ≥1 right
precordial lead) (Figure 2). Screening with a single ECG using CC
found five mutation carriers and zero non-carriers. Screening
with a single ECG using PC found 13 mutation carriers and 1 non-
carrier. The sensitivity of the PC was significantly higher, and no
significant differences were observed for specificity. Applying the
CC for the three repolarization patterns (CC3R) (type 1, 2, or 3
ECG .1 right precordial lead) found nine mutation carriers with
one non-carrier and with the PC for the three repolarization pat-
terns (PC3R) (type 1, 2, or 3 ECG ≥1 right precordial lead) found
16 mutation carriers with 9 non-carriers, meaning significantly
higher sensitivity but lower specificity. During follow-up (25.1+
14.3 months per patient), a total of 391 ECGs (3.2+2.3 per
patient) were made, and the cumulative results are presented in
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Table 1. Conventional criteria found 12 and PC found 18 carriers
(with one non-carrier in the second). The PC led to a significant
increase in sensitivity without a significant decrease in specificity.
The CC3R found 20 carriers with 2 non-carriers, and using the
PC3R, the number of carriers was not significantly higher with a
significant decrease in specificity.
With a single ECG, the PC had a positive likelihood ratio (PLR)
of 27.1, negative likelihood ratio (NLR) of 0.68, positive predictive
value (PPV) of 92.3%, and negative predictive value (NPP) of 75%.
When several exams were available, the PC3R and the CC3R were
not significantly different: PLR (37.5 vs. 20.8), NLR (0.56 vs. 0.51),
PPV (94.7 vs. 90.1%), and NPV (80 vs. 78.6%). Table 1 also presents
the number of detected carriers with one ECG against several
ECGs during follow-up.
Upward displacement of the right
precordial leads to the second intercostal
space
There is a concordant opinion that upward displacement of the
right precordial leads increases the number of ECGs that are diag-
nostic for the BrS. The right ventricular outflow tract has been
identified as the source of the electrocardiographic abnormalities
and arrhythmic activity in patients with the BrS, and higher IS is
anatomically related with it.9,11 However, no data prove whether
this manoeuvre increases the sensitivity to detect mutation carriers
without affecting its specificity.7 To ascertain this question, 70
family members (all older than 16 years), including 27 mutation
carriers, underwent an ECG recording with conventional lead
Figure 1 Genogram.
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. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Number of diagnosis in carriers and non-carriers with different criteria and with one electrocardiogram against
several electrocardiograms during follow-up
CC PC P value CC3R PC3R P value
Single spontaneous ECG Carrier 5 13 ,0.05 9 16 ,0.05
Sensibility 12.5 32.5 22.5 40
Non-carrier 0 1 .0.05 1 9 ,0.05
Specificity 100 98.8 98.8 89
Cumulative results during follow-up Carrier 12 18 ,0.05 20 23 .0.05
Sensitivity 30 45 50 57.5
Non-carrier 0 1 .0.05 2 11 ,0.05
Specificity 100 98.8 97.6 86.6
One ECG Several ECGs P value
Sensitivity
CC 12.5% 30% ,0.05
PC 32.5% 45% .0.05
CC3R 22.5% 50% ,0.05
PC3R 40% 57.5% ,0.05
Specificity
CC 100 100 –
PC 98.8 98.8 –
CC3R 98.8 97.6 .0.05
PC3R 89 86.6 .0.05
CC, conventional criteria (type 1 ECG. 1 right precordial lead); PC, proposed criteria (type 1 ECG ≥ 1 right precordial lead); CC3R, conventional criteria for the three
repolarization patterns (type 1, 2, or 3 ECG. 1 right precordial lead).
PC3R proposed criteria for the three repolarization patterns (type 1, 2, or 3 ECG ≥ 1 right precordial lead).
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placement and then with upward displacement of precordial leads
V1 and V2 to the second IS. Conventional lead position found
three carriers and zero non-carriers with the CC (sensitivity
11.1% and specificity 100%). Positioning of the right precordial
leads in the second IS leads to six more diagnosis (four carriers
and two non-carriers), thus augmenting the sensitivity to 25.9%
(P ¼ 0.1 ns) with an inferior specificity (95.3%). Thus, we have an
increase on sensitivity of 14.8% (95% confidence interval for the
difference: –6 to 22%), whereas the decrease on the specificity
lowers by only 4.7% (P ¼ ns).
Provocative test
Screening family members of patients with BrS with a non-
diagnostic spontaneous ECG must include a pharmacological pro-
vocative test, and if a type 1 ECG is induced in more than one right
precordial lead, the diagnostic is confirmed.9 Twenty-three adults
from this family (36.36+ 12.34 years; nine men), including 14 mu-
tation carriers (35.23+12.10 years; four men) and nine non-
carriers (38+13.22 years; five men), all with a non-diagnostic
spontaneous ECG, underwent provocative test using flecainide
(2 mg/kg/10 min, intravenous). Nine mutation carriers developed
a diagnostic pattern (type 1 ECG .1 right precordial lead), and
one of the non-carriers had a positive result (asymptomatic
male, 32-year-old: III17, Figure 1). This means that the provocative
test used to detect mutation carriers has a sensitivity of 64.3% and
specificity of 88.9%, with a PPV of 90% and NPV of 61.5%. All
the 14 mutation carriers repeated the provocative test with flecai-
nide after 1 year, and one (III58, Figure 1) presented a different
result: the first test was negative, and the second was positive (re-
peatability 92.9%).
After the provocative test, both PR and QRS intervals are signifi-
cantly longer in the carriers of loss-of-function SCN5A mutations
leading to premature truncation of the protein.12 In these 23
family members, before and after the provocative test, mutation
carriers compared with the non-carriers had, on average, a signifi-
cantly longer P-wave duration (before 111.5+ 14 vs. 93.8+14.1,
P ¼ 0.01 and after 122.3+ 13 vs. 107.5+ 17.5, P ¼ 0.03), a signifi-
cantly longer PR interval (before 194.6+ 21.8 vs. 164.4+ 26.1,
P ¼ 0.008 and after 224.6+ 27 vs. 180+ 35.5, P ¼ 0.004), and a
not significantly longer QRS duration (before 106.4+ 41.4 vs.
91.1+ 16.9, P ¼ ns and after 137.9+ 44.1 vs. 122.5+16.7, P ¼
ns). During pharmacological challenge, an ECG trend to higher
PR interval (30+24.2 vs. 20+15, P ¼ ns) and QRS width
(31.4+ 9.5 vs. 30+14.1, P ¼ ns) in carriers was noticed, but
these slight interval changes were not significant to discriminate
carriers vs. non-carriers.
Poor value of lead V3 in diagnosis
Brugada syndrome
A spontaneous diagnosis was done in the conventional position
(fourth IS) in 12 mutation carriers, and during follow-up, these
patients did 74 ECGs. The type 1 repolarization pattern was far
more frequent in leads V1 and V2: V1 with type 1 pattern in 54
(73%) ECGs and V2 with type 1 pattern in 49 (66.2%) ECGs.
There were only three (4.1%) ECGs with coved pattern in lead
V3, which means that this lead is less important for the diagnosis
of mutation carriers.
Non-invasive markers
Several ECG parameters were measured and analysed: P-wave
duration, PR interval, QRS duration, corrected QT, T peek-end
distance, transmural dispersion of repolarization (TDR) between
V1 and V3, and presence of aVR sign, fragmented QRS, and
early repolarization. Signal average ECG was obtained from the
adult population available (.16 years old). Mutation carriers
had, on average, significantly longer P-wave duration and PR and
QRS intervals and higher TDR compared with the non-carriers.
The prevalence of late potentials was higher in mutation carriers,
and individual SAECG parameters (QRSf, LAS, and RMS40) also
were significantly related to SCN5A gene (Table 2).
Invasive markers
Twenty-four family members (19 carriers of the mutation) did
EPS. Assessment of the ventricular arrhythmia inducibility was
performed through ventricular programmed stimulation at two
right ventricular sites (apex and outflow tract) at three basic
drive cycle lengths (600, 500, and 400 ms) with up to three extra-
stimuli. Ventricular arrhythmias were induced in three mutation
carriers and in none of the non-carriers. All inducible patients
had spontaneous Brugada ECG (Table 3). Mutation carriers com-
pared with the non-carriers had, on average, a not significantly
longer atria–His interval (98.94+ 28.73 vs. 76.8+3.9, P ¼ ns)
and significantly longer His–ventrical interval (48.18+ 7.15 vs.
38.8+ 6.42, P ¼ 0.016).
Figure 2 The electrocardiographic diagnosis of Brugada syn-
drome requires type 1 repolarization pattern in .1 right precor-
dial lead (II9) but it was recently proposed that an isolated lead
with coved-type electrocardiogram could be enough for the
diagnosis (III2).
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In the last 4 years among the 40 mutation carriers, 4 (10%) had
symptoms that could be related to BrS: 3 with syncope (one pre-
sented at the emergency department with sustained VT), and 1
with an episode of nocturnal agonal respiration (witnessed by his
wife and daughter): 2.5% event rate/year (Figure 3). Among non-
carriers, 4 also had syncope, with an aetiology concluded to be
vasovagal and with negative EPS. Events were between 16 and
61 years old.
Treatment
Four symptomatic patients with a diagnostic ECG received an
implantable cardioverter defibrillator (ICD). Asymptomatic
patients underwent EPS, and three were inducible for ventricular
arrhythmias and received an ICD. One patient with type 1 ECG
and asymptomatic and negative EPS received an ICD from a
second opinion from a different centre (Table 3).
Discussion
The electrocardiographic diagnosis of BrS requires type 1 repolar-
ization pattern in .1 right precordial lead (V1–V3), and type 2 or
3 repolarization patterns are only considered suggestive.9
However, this expert consensus has never been evaluated nor vali-
dated: some authors believe that types 2 and 3 also are diagnostic,
and other investigators recently proposed that an isolated lead
with coved-type ECG could be enough for the diagnosis because
these individuals have similar clinical profile and arrhythmic risk
as those with two affected leads. In our study, the sensitivity of
PC to detect carriers of the SCN5A mutation was significantly
higher than CC with no significant differences in the specificity.
The right ventricular outflow tract has been identified as the
source of the electrocardiographic abnormalities and arrhythmic
activity in this disease, and the presence of the pattern in one vs.
two leads may be more related with anatomical interindividual
variance than to a physiopathological condition.7,10,11 Using the
three repolarization patterns can be useful and appropriate in fa-
miliar screening, but the clinician must be aware that this approach
can mean higher sensitivity with lower specificity, particularly the
incomplete right bundle branch block pattern that is frequent in
the young and can mimic type 3 Brugada repolarization pattern.
Whatever criteria we use, the best single way to augment the sen-
sitivity of spontaneous ECG seems to be doing several examina-
tions related to the dynamic phenotypic presentation of this entity.
Specific SCN5A mutations correlate with the electrocardio-
graphic phenotype. Carriers of loss-of-function or missense
SCN5A mutations with more severe biophysical properties
develop more severe phenotypes associated with conduction dis-
orders, and this has been studied in terms of risk stratification.12 As
the sodium current dysfunction reflects on the fast response action
potential characteristic of atrial and ventricular myocytes and in the
fast-conducting Purkinje system, carriers have, on average, signifi-
cantly longer P-wave duration and PR and QRS intervals and
higher TDR compared with the non-carriers. The prevalence of
late potentials is higher in mutation carriers, and individual
SAECG parameter (QRSf, LAS, and RMS40) also is significantly
related to SCN5A gene mutation. These electrocardiographic para-
meters can participate as a screening tool to help the clinician dis-
tinguish between possible carriers and non-carriers. The presence
of a normal-high intra-atria and intra-ventricular conduction
(normal-high defined at least .75% of the normal range) can be
represented in a formula that needs to meet simultaneously six
conditions: PR ≥ 150, QRS ≥80, QTd .10, QRSf ≥90, LAS
≥26, and RMS40 ≤29 to be positive (high probability of carrying
a SCN5A mutation).13 This formula was applied to 46 adult
members of this family (including 25 mutation carriers), and it
was positive in 22 of the 25 carriers with 2 false positives in 21
non-carriers (sensitivity of 88% and specificity of 90.5%). The ac-
curacy to detect carriers in this family with this formula is much
higher than the characteristic ECG repolarization pattern.
It was recently reported that it may be possible to find a type 1
ECG in both carriers and non-carriers of SCN5A mutations among
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Non-invasive risk markers measured and analysed among mutation carriers and non-carriers
n Carriers Non-carriers P value
P-wave 122 119.66+15.47 91.96+12.4 ,0.001
PR interval 184.21+34.92 148.1+24.8 ,0.001
QRS interval 98.97+18.32 88.97+15.08 0.003
QT corrected 404.07+37.98 395.81+34.27 ns
T peak-end distance 85.64+25.83 85.56+20.89 ns
TDR 46.41+26.51 28,66+18.63 ,0.001
aVR sign 8 5 ns
Fragmented QRS 16 17 ns
Early repolarization 12 11 ns
Late potentials 46 52% 26.1% ,0.001
QRSf 104.74+9.67 92.11+12.91 ,0.001
LAS 41.33+9.64 32.43+14.33 0.009
RMS40 18.78+6.43 37.21+24.64 ,0.001
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families affected with BrS.14 This suggests that SCN5A mutations
are not necessary for the occurrence of BrS and that the diagnosis
is independent from the genetic results. Three individuals from this
family were found to be affected by Brugada type 1 diagnostic ECG
with a negative genotype. Among these three mutation-negative
BrS individuals, two (III1 and III18, Figure 1) had a spontaneous
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Non-invasive and invasive risk markers measured and analysed among mutation carriers

















II9 M (62/60/61) 25 Type 1 – – NAB Yes (20)/0/2
II10 F (69/–/–) 12 PP SAF – Refused No No
II12 F (50/–/–) 18 Normal Negative – No No
II14 M (53/52/53) 15 PP SAF – – Syn + VT Yes (12)/0/0
II15 F (46/45/–) 147 Normal Type 1 Negative No No
II19 M (39/37/–) 25 Normal Type 1 Negative No No
II29 F (51/49/–) 25 Type 1 – Negative No No
II30 F (49/47/–) 37 Type 1 – Negative No No
II33 F (64/63/–) 25 Type 2 Type 1 Refused No No
II34 M (49/46/–) 24 Type 1 IsoL – VF No Yes (20)/0/0
III2 M (20/18/–) 25 Type 1 – Negative No No
III4 F (31/30/–) 30 Type 1 IsoL – Negative No No
III5 F (30/26/–) 47 Type 1 – PolyM
VT
No Yes (44)/0/0
III6 F (31/–/–) 25 Normal Negative Negative No No
III10 F (33/31/–) 26 Type 1 – Negative No Yes (23)/0/0
III12 F (29/28/–) 19 Type 2 Type 1 Negative No No
III13 M (28/26/–) 19 Type 1 – Refused No No
III16 F (43/43/–) 24 Type 3 IsoL Type 1 Negative No No
III22 F (32/29/–) 26 Type 1 – Negative No No
III23 F (38/–/–) 25 Normal Negative – No No
III24 F (36/–/–) 25 Normal Negative – No No
III25 M (36/34/34) 32 Type 1 – – Syn Yes (27)/0/0
III26 M (36/34/–) 29 Type 1 – Negative No No
III27 F (47/46/–) 25 Type 1 – Negative No No
III30 M (29/27/–) 25 Type 1 – PolyM
VT
No Yes (16)/0/0
III48 M (28/28/–) 1 Type 1 IsoL – Refused No No
III49 M (24/22/–) 25 Normal Type 1 Negative No No
III51 F (27/25/–) 25 Normal Type 1 Negative No No
III52 F (20/18/16) 75 Type 1 IsoL Type 1 – Syn Yes (20)/0/0
III53 M (39/38/–) 17 Type 2 IsoL Type 1 Negative No No
III58 M (25/25/–) 25 Type 3 IsoL Negative/
positive
– No No
IVI F (4/3/–) 27 Type 1 IsoL – – No No
IV6 F (6/–/–) 15 Normal – – No No
IV7 M (13/–/–) 12 Normal – – No No
IV8 M (2/–/–) 7 Normal – – No No
IV9 M (6/–/–) 26 Normal – – No No
IV15 F (7/4/–) 26 Normal – – No No
IV17 M (7/–/–) 15 Normal – – No No
IV18 F (5/–/–) 26 Normal – – No No
IV22 M (6/3/–) 26 Type 1 IsoL – – No No
IsoL, isolated lead; LPHB, left posterior hemiblock; LAHB + RBBB, left anterior hemiblock + right bundle branch block; PP, permanent pacemaker; SAF, slow atrial fibrillation;
NAB, nocturnal agonic breathing; Syn, syncope; Syn + VT, syncope and sustained VT; VF, ventricular fibrillation; IS, intercostal space.
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type 1 ECG in the second IS, whereas one (III17, Figure 1) had a
type 1 ECG only after the administration of sodium channel block-
ers. The proposed formula previously mentioned was negative in
these three individuals. They are all asymptomatic, had a negative
response to ventricular stimulation, and are on close clinical
follow-up. Although these three individuals are considered
Brugada patients, we must discuss the possibility that a false-
positive result to unconventional position of the right precordial
leads and/or to drug challenge can occur. The provocative test
to unmask concealed forms of BrS is performed under the assump-
tion that the number of false positives (patients developing a type 1
ECG without being affected by the disease) is extremely low, but
the specificity of sodium channel blockage to identify unaffected
individuals is uncertain.7,15 As long as every single patient develop-
ing a type 1 ECG is defined as affected by BrS, it will be impossible
to find anyone who is defined as false positive, thus perpetuating
the perception that this manoeuvre and/or the pharmacological
test are 100% accurate. If a type 1 ECG appears in the absence
of a SCN5A mutation, should the diagnostic be definitive without
further corroboration? At present, no data derived from systematic
studies support or disprove the concept that upward displacement
of the right precordial leads and/or sodium channel blockers pro-
vides an accurate diagnosis of the disease.
Conclusions
A novel Nav1.5 mutation (c.664C.T; p.Arg222X) related to BrS
was described. The PC for BrS (type 1 ECG ≥1 right precordial
lead) should be implemented, so revision of the consensus criteria
should be considered. We suggest that conduction parameters in
the Nav1.5-dependent areas (atrial muscle, Purkinje fibres, and
ventricular muscle) can yield diagnostic information in differentiat-
ing between SCN5A mutation carriers whenever the genetic test is
not available. Three individuals from this family were found to be
affected by Brugada type 1 diagnostic ECG with a negative geno-
type. They are the evidence that there is much to know about
the genotype–phenotype relationship in BrS, but we should con-
sider that they also can represent a false-positive response to un-
conventional lead position and/or to drug challenge.
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Figure 3 Kaplan–Meier curve representing events (symptom-
atic manifestation) on mutation carriers since birth.
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